Table 2. Clinical presentation and radiological features of antiphospholipid antibody-associated chorea.

	PUMCH(n=13)	Literature(n=167)	Overall(n=180)
Episodes
=1	9/12 (75)	111/167 (66.5)	120/179 (67.0)
>1	3/12 (25)	56/167 (33.5)	59/179 (33.0)
Mean (range)	1.2 (1, 2)	1.5 (1, 6)	1.5 (1, 6)
Localisation
Unilateral or bilateral
Bilateral	8/12 (66.7)	86/148 (58.1)	94/160 (58.8)
Unilateral	4/12 (33.3)	62/148 (41.9)	66/160 (37.5)
Upper limb, lower limb, both
Both	10/12 (83.3)	92/105 (87.6)	102/117 (87.2)
Upper limb	2/12 (16.7)	13/105 (12.4)	15/117 (12.8)
Lower limb	0/12 (0)	0/105 (0)	0/117 (0)
Head or face involvement	9/12 (75)	74/102 (72.5)	83/114 (72.8)
Precipitating factors
Oral contraceptive	0/12 (0)	14/167 (8.4)	14/179 (7.8)
Pregnancy	1/12 (8.3)	12/167 (7.2)	13/179 (7.3)
None	10/12 (83.3)	139/167 (83.2)	149/179 (83.2)
Duration from onset to improvement
Days	0/12 (0)	2/154 (1.3)	2/166 (1.2)
Weeks	0/12 (0)	30/154 (19.5)	30/166 (18.1)
Months	12/12 (100)	85/154 (55.2)	97/166 (58.4)
Years	0/12 (0)	37/154 (24.0)	37/166 (22.3)
Duration of follow-up, months
Median (range)	24.9 (3.1, 97.1)	18 (0.2, 588)	22.8 (0.2, 588)
MRI
Availability	11/13 (84.6)	124/167 (74.3)	135/180 (75.0)
Abnormality	7/11 (63.6)	58/124 (46.8)	65/135 (48.1)
Basal ganglia lesions	1/7 (14.3)	19/58 (32.8)	20/65 (30.8)
White matter hyperintensities	5/7 (71.4)	25/42 (59.5)	30/49 (61.2)
Atrophy	0/7 (0)	4/42 (9.5)	4/49 (8.2)
PET-CT/MRI
Availability	5/13 (38.5)	11/167 (6.6)	16/180 (8.9)
Abnormality	5/5 (100.0)	11/11 (100.0)	16/16 (100.0)
Hypermetabolism of basal ganglia	5/5 (100.0)	11/11 (100.0)	16/16 (100.0)
Hypometabolism of other regions	3/5 (60.0)	3/11 (27.3)	6/16 (37.5)
Repeat in complete remission	1/5 (20.0)	5/11 (45.5)	6/16 (37.5)
Back to normal	1/1 (100.0)	5/5 (100.0)	6/6 (100.0)

PETpositron emission tomographyPUMCHPeking Union Medical College Hospital